$10.48-1.2%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Just reported
From Design Therapeutics, Inc.'s results release of November 4, 2026; its quarterly report has since been filed.
Actual
$0.00
Guided
—
No guide given
Actual
-$0.32
Guided
—
No guide given
Actual
-$22.2M
Guided
—
No guide given
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$20.3M | -$17M | -19.36% |
| Profit per share | -$0.32 | -$0.30 | -6.67% |
| Free Cash Flow | -$15.4M | -$11.2M | -37.91% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Design Therapeutics, Inc. reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“We remain focused on evaluating DT-216P2 over longer treatment durations and preparing for the next stage of clinical development in Friedreich ataxia,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC ® gene targeted chimera small molecules. The company’s GeneTAC ® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC ® programs, DT-216P2, in development for patients with Friedreich ataxia, DT-168, for Fuchs endothelial corneal dystrophy, and DT-818, for myotonic dystrophy type-1, the company is advancing a program in Huntington’s disease. Discovery efforts are underway for multiple genomic medicines.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Design Therapeutics, Inc.’s Item 2.02 8-K filed November 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.